Sfoglia per AUTORE
TANI M
Collezione AO Ordine Mauriziano
Items : 2
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.
2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
Foà R; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Del Giudice I; Guarini A; De Propris MS; Nanni M; De Novi LA; Neri A; Albano F; Vitale C; Visentin A; Mattiello V; Pietrasanta D; Molinari MC; Giordano A; Gottardi D; Liberati AM; Patrizi VB; Deodato M; Galieni P; Arcari A; Musuraca G; Levato L; Tani M; Marchetti M; Rigolin GM; et alii...
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.
2021
AOU Alessandria
AO Ordine Mauriziano
AOU Alessandria
AO Ordine Mauriziano
Piciocchi A; Guarini A; Rigolin GM; Neri A; Fazi P; Nanni M; Raponi S; Della Starza I; De Propris MS; Del Giudice I; Ruocco V; Murru R; Laurenti L; Varettoni M; Ibatici A; Chiarenza A; Gentile M; Molinari A; Gozzetti A; Zinzani PL; Musuraca G; Gottardi D; Tani M; Re F; Liberati AM; Orsucci L; Ilariucci F; Di Renzo N; Stelitano C; et alii...